Breast Cancer Liquid Biopsy Market – Industry analysis and forecast (2019-2026) by Circulating Biomarker, End user and Region.

Breast Cancer Liquid Biopsy Market – Industry analysis and forecast (2019-2026) by Circulating Biomarker, End user and Region.

Market Scenario

Breast Cancer Liquid Biopsy Market is expected to reach US$ XX Mn by 2026 at a CAGR of XX% during the forecast period. Breast Cancer Liquid Biopsy market A breast cancer liquid biopsy is a simple and non-invasive alternative to surgical biopsies which enables doctors to discover a range of information about a tumor through a simple blood sample. Traces of cancer's DNA in the blood can give clues about the treatments that are most likely to work for that patient. In addition, breast cancer liquid biopsy may improve therapies and achieve better clinical outcomes in patients. Breast cancer liquid biopsy is highly fragmented due to technological advancement and innovations in medical treatment. The increasing prevalence of breast cancer, preference for non-invasive procedures, initiatives undertaken by government and global health organizations, technological advancement to augment market revenues, rising emphasis on personalized medicine, and availability of funding for liquid biopsy R & D would create commercial market opportunities. However, the high cost of care for breast cancer patients continues to be the major hindrance to the market growth. Breast cancer liquid biopsy market is segmented by circulating biomarker, end use, and region. Among circulating biomarker, circulating tumor cells and cell-free DNA is considered attractive market segment and is expected to hold a significant share of the market in the coming years. Growth can be attributed to factors such as technological advancement and innovations in medical treatment. Circulating biomarker segment would continue to dominate the market during the forecast period owing to most of the diagnostic, prognostic, and therapy-predictive procedures, which aim to improve the overall level of personalization. Among regions, the North America is expected to grow at the highest CAGR of XX% during the forecast period due to easy accessibility and high adoption of advanced diagnostic technologies (such as PCR and NGS) among healthcare professionals, rising prevalence of breast cancer in the US and Canada, technological advancements in breast cancer liquid biopsy products, and growing public and private funding to support research activities in the field. The Asia Pacific is expected to grow rapidly due to rising healthcare awareness along with increasing geriatric population coupled with governments and companies trying to keep growing cancer prevalence rates under control in the region. For instance, the Indian government developed a National Programme for Prevention and Control of Breast Cancer among low-income women in a public breast cancer screening program. China, India, and Japan are the major contributors to the region’s growth. The objective of the report is to present a comprehensive analysis of global breast cancer liquid biopsy market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding global breast cancer liquid biopsy market dynamics, structure by analyzing the market segments and project the global breast cancer liquid biopsy market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product portfolio, Growth strategies, and regional presence in the global breast cancer liquid biopsy market make the report investor’s guide.

The Scope of the Breast Cancer Liquid Biopsy Market:

Breast Cancer Liquid Biopsy Market, by Circulating Biomarker

• Circulating Tumour Cells (CTCs) • Cell-free DNA (cfDNA) • Extracellular Vehicles (EVs) • Other Circulating Biomarkers • Liquid Biopsy Market, by End User • Reference Laboratories • Hospitals and Physician Laboratories • Other End Users

Breast Cancer Liquid Biopsy market, by Region

• North America • Europe • APAC • Latin America • MEA

Key Players of the Breast Cancer Liquid Biopsy Market

• QIAGEN N.V. • Roche Diagnostics • Bio-Rad Laboratories • Myriad Genetics • Menarini Silicon Biosystems • Illumina • Cynvenio Biosystems, Inc • Genomic Health, Inc. • Thermo Fisher Scientific Inc. • Fluxion Biosciences, Inc • Biodesix, Inc. • Guardant Health, Inc. • Isogen Life Science B.V. Bowel Management Systems Market

Table of Contents

Breast Cancer Liquid Biopsy Market

1. INTRODUCTION 1.1 Report Description 1.1.1 Objectives of the Study 1.1.2 Market Scope 1.1.3 Years considered in the study 1.1.4 Currency 1.1.5 Stakeholders 1.2 Target Audience 1.3 Key Takeaways 2. RESEARCH METHODOLOGY 2.1 Research Methodology 2.2 Market Definition 2.3 Assumptions and Acronyms Used 2.4 Data Sources 2.4.1 Secondary 2.4.1.1 Paid 2.4.1.2 Unpaid 2.4.2 Primary 2.5 Analyst tools and models 3. EXECUTIVE SUMMARY 3.1 Breast Cancer Liquid Biopsy Market Overview 3.1.1 Breast Cancer Liquid Biopsy Market : By Circulating Biomarker 3.1.2 Breast Cancer Liquid Biopsy Market : By End User 3.1.3 Breast Cancer Liquid Biopsy Market : By Region 4. BREAST CANCER LIQUID BIOPSY MARKET OUTLOOK 4.1 Breast Cancer Liquid Biopsy Market : Market Definition, Segmentation and Scope of Study 4.2 Breast Cancer Liquid Biopsy Market : Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Breast Cancer Liquid Biopsy Market : Competitive Analysis 4.3.1 Key Strategic Initiatives 4.3.2 Regional Presence 4.3.3 Product Overview 4.4 Breast Cancer Liquid Biopsy Market : Porter’s Analysis 4.5 Breast Cancer Liquid Biopsy Market : PESTEL Analysis 4.6 Breast Cancer Liquid Biopsy Market : Product Benchmark Analysis 4.7 Breast Cancer Liquid Biopsy Market : Company Market Share Analysis 4.8 Breast Cancer Liquid Biopsy Market : Key Findings 4.8.1 Breast Cancer Liquid Biopsy Market : Top Wining Strategies 4.8.2 Breast Cancer Liquid Biopsy Market : Top Investment Pockets 4.8.3 Breast Cancer Liquid Biopsy Market : Top Impacting Factors 4.8.4 Key Trends in Global Breast Cancer Liquid Biopsy Market 5. BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER 5.1 Breast Cancer Liquid Biopsy Market : Circulating Biomarker segment Market Share analysis 5.2 Breast Cancer Liquid Biopsy Market : Circulating Biomarker segment Market Size and Forecast 2019-2026 5.3 Breast Cancer Liquid Biopsy Market by Circulating Tumour Cells 5.4 Breast Cancer Liquid Biopsy Market by Cell-Free DNA 5.5 Breast Cancer Liquid Biopsy Market by Extracellular Vehicles 5.6 Breast Cancer Liquid Biopsy Market Benchmarking By Circulating Biomarker 5.7 Breast Cancer Liquid Biopsy Market by Circulating Biomarker : Key Trends 5.8 Breast Cancer Liquid Biopsy Market by Circulating Biomarker : Key Developments 6. BREAST CANCER LIQUID BIOPSY MARKET , BY END USER 6.1 Breast Cancer Liquid Biopsy Market : End User segment Market Share Analysis 6.2 Breast Cancer Liquid Biopsy Market : End User segment Market Size and Forecast 2019-2026 6.3 Breast Cancer Liquid Biopsy Market by Reference Laboratories 6.4 Breast Cancer Liquid Biopsy Market by Hospitals and Physician Laboratories 6.5 Breast Cancer Liquid Biopsy Market by Other End Users 6.6 Breast Cancer Liquid Biopsy Market Benchmarking By End User 6.7 Breast Cancer Liquid Biopsy Market by End User: Key Trends 6.8 Breast Cancer Liquid Biopsy Market by End User: Key Developments 7. BREAST CANCER LIQUID BIOPSY MARKET , BY GEOGRAPHY 7.1 Breast Cancer Liquid Biopsy Market : Geography segment Market Share Analysis 7.2 Breast Cancer Liquid Biopsy Market : Geography segment Market Size and Forecast 2019-2026 7.3 North America 7.3.1 Overview 7.3.2 Breast Cancer Liquid Biopsy Market Size and Forecast, by Circulating Biomarker 2019-2026 7.3.3 Breast Cancer Liquid Biopsy Market Share Analysis , by Circulating Biomarker 2019-2026 7.3.4 Breast Cancer Liquid Biopsy Market Size and Forecast, by End User 2019-2026 7.3.5 Breast Cancer Liquid Biopsy Market Share Analysis , by End User 2019-2026 7.4 Europe 7.4.1 Overview 7.4.2 Breast Cancer Liquid Biopsy Market Size and Forecast, by Circulating Biomarker 2019-2026 7.4.3 Breast Cancer Liquid Biopsy Market Share Analysis , by Circulating Biomarker 2019-2026 7.4.4 Breast Cancer Liquid Biopsy Market Size and Forecast, by End User 2019-2026 7.4.5 Breast Cancer Liquid Biopsy Market Share Analysis , by End User 2019-2026 7.5 Asia Pacific 7.5.1 Overview 7.5.2 Breast Cancer Liquid Biopsy Market Size and Forecast, by Circulating Biomarker 2019-2026 7.5.3 Breast Cancer Liquid Biopsy Market Share Analysis , by Circulating Biomarker 2019-2026 7.5.4 Breast Cancer Liquid Biopsy Market Size and Forecast, by End User 2019-2026 7.5.5 Breast Cancer Liquid Biopsy Market Share Analysis , by End User 2019-2026 7.6 Latin America, Middle East and Africa 7.6.1 Overview 7.6.2 Breast Cancer Liquid Biopsy Market Size and Forecast, by Circulating Biomarker 2019-2026 7.6.3 Breast Cancer Liquid Biopsy Market Share Analysis , by Circulating Biomarker 2019-2026 7.6.4 Breast Cancer Liquid Biopsy Market Size and Forecast, by End User 2019-2026 7.6.5 Breast Cancer Liquid Biopsy Market Share Analysis , by End User 2019-2026 7.7 Breast Cancer Liquid Biopsy Market Benchmarking By Geography 7.8 Breast Cancer Liquid Biopsy Market by Geography : Key Trends 7.9 Breast Cancer Liquid Biopsy Market by Geography : Key Developments 8. COMPITITIVE LANDSCAPE 8.1 Breast Cancer Liquid Biopsy Market Share/ Positioning Analysis 8.2 Breast Cancer Liquid Biopsy Market: Key Innovators 8.3 Breast Cancer Liquid Biopsy Market : Company Profiles 8.3.1 QIAGEN N.V. 8.3.1.1 Overview 8.3.1.2 Product/Service Portfolio 8.3.1.3 Key Financials 8.3.1.4 Strategic Initiatives 8.3.1.5 SWOT Analysis 8.3.1.6 Competitive Assessment 8.3.2 Roche Diagnostics 8.3.2.1 Overview 8.3.2.2 Product/Service Portfolio 8.3.2.3 Key Financials 8.3.2.4 Strategic Initiatives 8.3.2.5 SWOT Analysis 8.3.2.6 Competitive Assessment 8.3.3 Bio-Rad Laboratories 8.3.3.1 Overview 8.3.3.2 Product/Service Portfolio 8.3.3.3 Key Financials 8.3.3.4 Strategic Initiatives 8.3.3.5 SWOT Analysis 8.3.3.6 Competitive Assessment 8.3.4 Myriad Genetics 8.3.4.1 Overview 8.3.4.2 Product/Service Portfolio 8.3.4.3 Key Financials 8.3.4.4 Strategic Initiatives 8.3.4.5 SWOT Analysis 8.3.4.6 Competitive Assessment 8.3.5 Menarini Silicon Biosystems 8.3.5.1 Overview 8.3.5.2 Product/Service Portfolio 8.3.5.3 Key Financials 8.3.5.4 Strategic Initiatives 8.3.5.5 SWOT Analysis 8.3.5.6 Competitive Assessment 8.3.6 Illumina 8.3.6.1 Overview 8.3.6.2 Product/Service Portfolio 8.3.6.3 Key Financials 8.3.6.4 Strategic Initiatives 8.3.6.5 SWOT Analysis 8.3.6.6 Competitive Assessment 8.3.7 Cynvenio Biosystems, Inc 8.3.7.1 Overview 8.3.7.2 Product/Service Portfolio 8.3.7.3 Key Financials 8.3.7.4 Strategic Initiatives 8.3.7.5 SWOT Analysis 8.3.7.6 Competitive Assessment 8.3.8 Genomic Health, Inc. 8.3.8.1 Overview 8.3.8.2 Product/Service Portfolio 8.3.8.3 Key Financials 8.3.8.4 Strategic Initiatives 8.3.8.5 SWOT Analysis 8.3.8.6 Competitive Assessment 8.3.9 Thermo Fisher Scientific Inc. 8.3.9.1 Overview 8.3.9.2 Product/Service Portfolio 8.3.9.3 Key Financials 8.3.9.4 Strategic Initiatives 8.3.9.5 SWOT Analysis 8.3.9.6 Competitive Assessment 8.3.10 Fluxion Biosciences, Inc 8.3.10.1 Overview 8.3.10.2 Product/Service Portfolio 8.3.10.3 Key Financials 8.3.10.4 Strategic Initiatives 8.3.10.5 SWOT Analysis 8.3.10.6 Competitive Assessment 8.3.11 Biodesix, Inc. 8.3.11.1 Overview 8.3.11.2 Product/Service Portfolio 8.3.11.3 Key Financials 8.3.11.4 Strategic Initiatives 8.3.11.5 SWOT Analysis 8.3.11.6 Competitive Assessment 8.3.12 Guardant Health, Inc. 8.3.12.1 Overview 8.3.12.2 Product/Service Portfolio 8.3.12.3 Key Financials 8.3.12.4 Strategic Initiatives 8.3.12.5 SWOT Analysis 8.3.12.6 Competitive Assessment 8.3.13 Isogen Life Science B.V. 8.3.13.1 Overview 8.3.13.2 Product/Service Portfolio 8.3.13.3 Key Financials 8.3.13.4 Strategic Initiatives 8.3.13.5 SWOT Analysis 8.3.13.6 Competitive Assessment 9. CONSOLIDATION 9.1 Breast Cancer Liquid Biopsy Market: Mergers and Acquisitions 9.1.1 Overview 9.1.2 Breast Cancer Liquid Biopsy Market : Key Drivers – By Region 9.1.3 Breast Cancer Liquid Biopsy Market : M&A Breakdown 9.1.3.1 Circulating Biomarker-Based 9.1.3.2 End Users Based 9.1.3.3 Niche Based 9.1.3.4 Region Based 9.1.3.5 Asset & Non-Asset Based 9.1.3.6 Venture Capitalist Based 9.2 Fragmentation of Breast Cancer Liquid Biopsy Market 9.3 Breast Cancer Liquid Biopsy Market : Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements 9.4 Breast Cancer Liquid Biopsy Market - New/Emerging Models of Partnerships : Key Examples 9.5 Breast Cancer Liquid Biopsy Market : New/Emerging Business Models : Key Examples 9.6 Breast Cancer Liquid Biopsy Market - Changing Investment Paradigm : Focused areas by Key Players 9.7 Breast Cancer Liquid Biopsy Market - Patent Analysis 10. Breast Cancer Liquid Biopsy Market : LIST OF TABLES 11. Breast Cancer Liquid Biopsy Market: LIST OF FIGURES

About This Report

Report ID12622
Published Date
Contact Us
Call Now